TTM Family | NeuShen Therapeutics completes nearly $20 million Pre-A round financing
NeuShen Therapeutics, a biotechnology company focused on the development of innovative drugs for the central nervous system (CNS) and possessing dual platforms for adenovirus-associated virus (AAV) gene therapy and small molecule drug therapy, recently announced the completion of nearly $20 million in Pre-A round financing. This round of financing was led by Lapam Capital, with TTM Capital participating.
NeuShen Therapeutics, a biotechnology company focused on the development of innovative drugs for the central nervous system (CNS) and possessing dual platforms for adenovirus-associated virus (AAV) gene therapy and small molecule drug therapy, recently announced the completion of nearly $20 million in Pre-A round financing. This round of financing was led by Lapam Capital, with TTM Capital participating.
The successful completion of the Pre-A round of financing highlights the CNS drug development capabilities of the NeuShen team. The company will officially launch its dual-platform independent research and development to establish a product pipeline based on AAV gene therapy and small molecule therapy. The funds from this round of financing will be used to build a professional team and accelerate the establishment of independent CNS research platforms in both China and the United States, as well as the development of innovative drugs.
With the extension of human lifespan and the increasing pressure of an aging society, CNS diseases are considered one of the major causes of disability and death. However, their diagnosis and treatment lag far behind other disease areas, necessitating more attention and measures to address the increasingly severe challenges.
Since its establishment, the NeuShen team has set clear goals, focusing on developing innovative treatments for central nervous system diseases to alleviate the suffering and burden of patients and their families. In the past few months, NeuShen has formulated a clear and feasible R&D strategy and assembled a core team of experts with extensive experience in the CNS industry, achieving significant progress in both small molecule projects and gene therapy projects based on a novel AAV vector. NeuShen has also established partnerships with several global pharmaceutical companies and academic institutions.
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
